Antegren Brand Rejected Due To Possible Confusion With Ativan, Integrilin
This article was originally published in The Pink Sheet Daily
Executive Summary
Elan and Biogen Idec agreed to change the name of the multiple sclerosis monoclonal antibody natalizumab from Antegren to Tysabri after FDA expressed concern over potential drug name mix-ups